Home » Topics » Regulatory » EMA

EMA
RSS

FDA and EMA accepts regulatory submissions of talazoparib for review

June 8, 2018

EMA grants PRIME designation for dilanubicel

June 7, 2018

EMA grants PRIME designation to AT-132 for the treatment of X-linked myotubular myopathy

June 6, 2018

Myalepta receives positive CHMP opinion for generalized and partial lipodystrophy

June 5, 2018

EMA committee backs approval of trastuzumab biosimilar Trazimera

June 4, 2018

EMA committee recommends approval of Translarna for younger children with DMD

June 4, 2018

EMA CHMP recommends approval of Sandoz adalimumab biosimilar

June 4, 2018

Aimovig receives positive CHMP opinion for the prevention of migraine

June 4, 2018

Exondys receives negative CHMP opinion

June 4, 2018

Tegsedi receives positive opinion in Europe

June 4, 2018

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...